Quality Control First: Key Laboratory Management Points for Five Anti-Epileptic Drug Concentration Determination LC-MS/MS Kits

Kit Composition and Performance Verification Requirements

Five-item antiepileptic drug concentration assay kits (liquid chromatography-tandem mass spectrometry) typically include calibrators, quality controls, internal standards, and necessary pretreatment consumables. Before introducing a kit, laboratories should perform complete performance verification. According to general industry guidelines, verification content should include: precision (intra-assay and inter-assay coefficients of variation generally required to be less than 15%), accuracy (through spike recovery or comparison with reference methods), linear range (covering common clinical concentration intervals), lower limit of quantification, and limit of detection. In addition, matrix effects need to be specifically evaluated, because matrix differences in plasma from different patients may cause ion suppression or enhancement of antiepileptic drugs. The use of post-column internal standard addition or blank matrix verification can reduce such bias.

Sample Pretreatment and Optimization of Chromatographic and Mass Spectrometric Conditions

This kit mostly uses protein precipitation or solid-phase extraction to remove protein interference. When establishing the method, laboratories should strictly follow the conditions recommended in the instructions, but may fine-tune the mobile phase ratio or column temperature according to the characteristics of their own liquid chromatography system to improve the separation of the five drugs. Mass spectrometric parameters such as source voltage and collision energy should be optimized by direct injection to ensure that the signal-to-noise ratio of each drug's characteristic ion pairs (such as quantitative ions and qualitative ions) meets requirements. During routine operation, retention time and peak area drift should be monitored, and timely maintenance should be performed.

Calibration and Quality Control Strategy

Calibrators should cover high, medium, and low concentration points within the linear range, and in principle should include no fewer than 6 nonzero points. For quality control materials, it is recommended to use at least two concentration levels (normal and abnormal concentrations), and to evaluate the stability of the quality control materials in the kit. Each testing batch must be accompanied by quality control, and judgment should be made using Westgard multirules. When quality control results show one-sided shift or continuous trend, the status of calibrators, internal standards, chromatographic column, or mass spectrometric ion source should be investigated. It is worth noting that kits from different lot numbers may differ, and linearity and accuracy should be re-verified when changing lot numbers.

Common Problems and Solutions

In actual operation, common problems include: unstable internal standard response (which may result from failure of the internal standard solution or carryover in the injection system), drug peak tailing or splitting (mostly due to contamination of the chromatographic column or failure of the guard column), and abnormal recovery of some drugs caused by matrix effects (sample dilution or a different pretreatment method may be attempted). Laboratories should establish standard operating procedures and regularly train operators, and record problems and corrective measures. Participation in external quality assessment or sample comparison with other laboratories helps identify systematic bias. In summary, strict quality control management is the cornerstone for realizing the clinical value of the kit.